WALDENSTRÖM MACROGLOBULINEMIA
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial is testing a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. It is for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. The main go…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: C. Babis Andreadis • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to wipe out cancer protein in Tough-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new oral drug, BGB-16673, designed to destroy a protein called BTK that helps certain blood cancers grow. The trial includes about 645 people with various B-cell cancers (like lymphoma and leukemia) that have come back or not responded to prior treatments. The …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets Hard-to-Treat blood cancers in chinese trial
Disease control Recruiting nowThis study tests a new drug called BGB-16673 for people in China with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The drug works by breaking down a protein that helps cancer cells grow. The trial has two parts: first, finding the…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Engineered immune cells get a metabolic boost to fight blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new version of CAR T-cell therapy that has been modified to improve its energy use, potentially making the cells more effective. It is for adults with certain types of B-cell lymphoma or chronic lymphocytic leukemia that have come back or not r…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for Hard-to-Treat lymphoma? early trial of ABBV-291 begins
Disease control Recruiting nowThis early-stage trial is testing a new drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or stopped responding to treatment. The study will first find the safest dose, then check if the drug can shrink tumors. About 165 participants will take part wor…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New hope for rare blood cancer: pacritinib trial opens for patients who need better options
Disease control Recruiting nowThis study tests whether the drug pacritinib is safe and effective for adults with Waldenström macroglobulinemia, a rare blood cancer, when previous treatments have stopped working. About 30 participants will receive pacritinib and be monitored for tumor shrinkage and side effect…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Shayna Sarosiek, MD • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New pill hopes to tackle tough lymphoma
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called LP-168, taken as a pill, in adults with B-cell lymphoma that has come back or not responded to standard treatments. The study aims to find the safest dose and check for side effects in about 200 participants. It is too…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Elderly lymphoma Patients' Well-Being under the microscope
Knowledge-focused Recruiting nowThis study follows 150 adults aged 70 and older with low-grade non-Hodgkin lymphoma to see how their quality of life changes during treatment. Researchers will use questionnaires to track well-being from diagnosis through one year after therapy starts. The goal is to identify whi…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC